(Q37140813)

18 August 2017

1 reference

title

Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly (English)

1 reference

18 August 2017

author

Jean-Claude Souberbielle

series ordinal

2

object named as

Jean-Claude Souberbielle

1 reference

18 August 2017

3

Philippe Chanson

1 reference

18 August 2017

Laure Cazabat

1

1 reference

18 August 2017

publication date

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

11

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

129-139

1 reference

https://scigraph.springernature.com/pub.10.1007/s11102-008-0113-7

18 August 2017

exact match

0 references

cites work

Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11102-008-0113-7

Acromegaly and end-stage renal disease: a diagnostic challenge.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11102-008-0113-7

The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly

21 January 2018

1 reference

12 December 2020

Consensus statement: medical management of acromegaly

1 reference

12 December 2020

Gender and age in the biochemical assessment of cure of acromegaly

1 reference

12 December 2020

Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients

1 reference

12 December 2020

Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels

1 reference

12 December 2020

Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly

1 reference

12 December 2020

Growth hormone assay standardization: a biased view?

1 reference

12 December 2020

Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.

1 reference

12 December 2020

Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.

1 reference

12 December 2020

The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly

1 reference

12 December 2020

Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice.

1 reference

12 December 2020

Critical study of the growth hormone response to dynamic tests and the insulin growth factor assay in acromegaly after microsurgery

1 reference

12 December 2020

Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly

1 reference

12 December 2020

Estrogen regulation of growth hormone action.

1 reference

12 December 2020

The growth hormone and insulin-like growth factor axis: its manipulation for the benefit of growth disorders in renal failure.

1 reference

12 December 2020

Active acromegaly and gigantism: some clinical characteristics of 50 patients

1 reference

12 December 2020

[Recommendations for the standardization of growth hormone assays]

1 reference

12 December 2020

Current concepts in the biochemical assessment of the patient with acromegaly

1 reference

12 December 2020

Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society

1 reference

12 December 2020

Growth hormone heterogeneity in human pituitary and plasma

1 reference

12 December 2020

Growth hormone assay standardization: an important clinical advance

1 reference

12 December 2020

Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly

1 reference

12 December 2020

Editorial: acromegaly--consensus, what consensus?

1 reference

12 December 2020

Effect of sex and assay method on serum concentrations of growth hormone in patients with acromegaly and in healthy controls

1 reference

12 December 2020

The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly

1 reference

12 December 2020

Hormonal diagnosis of GH hypersecretory states.

1 reference

12 December 2020

Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?

1 reference

12 December 2020

Consensus statement on the standardisation of GH assays

1 reference

12 December 2020

Plasma growth hormone (GH) responses to corticotropin-releasing hormone in patients with acromegaly--the effect of dexamethasone pretreatment and the comparison with GH responses to thyrotropin-releasing hormone, gonadotropin-releasing hormone and G

1 reference

12 December 2020

Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders

1 reference

12 December 2020

Clinical significance of the growth hormone response to vasoactive intestinal peptide and gonadotropin-releasing hormone in acromegaly

1 reference

12 December 2020

The relationship between serum GH and serum IGF-I in acromegaly is gender-specific

1 reference

12 December 2020

Pitfalls in the biochemical assessment of acromegaly

1 reference

12 December 2020

Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.

1 reference

12 December 2020

Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.

1 reference

12 December 2020

Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly

1 reference

12 December 2020

A re-evaluation of the prolactin-releasing activity of growth hormone-releasing hormone in acromegaly in vivo

1 reference

12 December 2020

Serum growth hormone measurements in clinical practice: An audit of performance from the UK National External Quality Assessment scheme

1 reference

12 December 2020

Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations

1 reference

12 December 2020

Criteria for cure of acromegaly: a consensus statement

1 reference

12 December 2020

Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women

1 reference

12 December 2020

Pulsatile growth hormone release in normal women during the menstrual cycle

1 reference

12 December 2020

Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies

1 reference

12 December 2020

Less is more risky? Growth hormone and insulin-like growth factor 1 levels and cardiovascular risk

1 reference

12 December 2020

Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels

1 reference

12 December 2020

Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease

1 reference

12 December 2020

Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up

1 reference

12 December 2020

Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits?

1 reference

12 December 2020

Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.

1 reference

12 December 2020

Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly

1 reference

12 December 2020

Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue

1 reference

12 December 2020

Prediction of efficacy of octreotide therapy in patients with acromegaly.

1 reference

12 December 2020

Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide

1 reference

12 December 2020

Adequacy of current postglucose GH nadir limit (< 1 µg/l) to define long-lasting remission of acromegalic disease

1 reference

12 December 2020

Acromegaly associated with type 2 diabetes showing normal IGF-1 levels under poorly controlled glycemia.

1 reference

12 December 2020

Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature

1 reference

12 December 2020

Acromegaly or chronic renal failure: a diagnostic dilemma

1 reference

12 December 2020

TRH/GnRH test in acromegaly. Long-term follow-up experience with successfully treated patients

1 reference

12 December 2020

10.1007/S11102-008-0113-7

Identifiers

DOI

1 reference

18 August 2017

1 reference